Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Smits

Showing results (341-350 of 343) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 343 results.
Eclinicalmedicine|June 20, 2023
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort studyQuincy Hofsink, Sabine Haggenburg, Birgit I Lissenberg-Witte, et al.
JAMA Oncology|August 11, 2022
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19Sabine Haggenburg, Quincy Hofsink, Birgit I Lissenberg-Witte, et al.
Haematologica|May 29, 2025
T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccinesCilia R Pothast, Quincy Hofsink, Sabine Haggenburg, et al.
Pageof 35

Showing results (341-350 of 343) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 343 results.
Eclinicalmedicine|June 20, 2023
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort studyQuincy Hofsink, Sabine Haggenburg, Birgit I Lissenberg-Witte, et al.
JAMA Oncology|August 11, 2022
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19Sabine Haggenburg, Quincy Hofsink, Birgit I Lissenberg-Witte, et al.
Haematologica|May 29, 2025
T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccinesCilia R Pothast, Quincy Hofsink, Sabine Haggenburg, et al.
Pageof 35